Epigenetic Regulation in Alzheimer’s Disease: Roles of DNA Methylation and Histone Regulation
DOI:
https://doi.org/10.61173/b5w9nk92Keywords:
Alzheimer’s Disease, DNA methylation, Histone modificationAbstract
A l z h e i m e r ’s d i s e a s e ( A D ) i s a p r o g r e s s i v e neurodegenerative disorder and one of the leading causes of dementia. The most significant known risk factor for AD is aging, and the increasing number of elderly people in low- and middle-income countries leads to an increase in AD incidence. Increasingly, age-related epigenetic changes are recognized as key drivers of the onset and progression of AD. This review examines how epigenetic processes, including DNA methylation and histone modification, affect amyloid-beta (Aβ) generation and clearance and tau protein pathology development, which are the two main features of AD. The genes APP, BACE1, PSEN1, and APOE show abnormal DNA methylation patterns, which result in elevated Aβ production and reduced clearance mechanisms. Alterations in histone acetylation and methylation patterns lead to synaptic dysfunction, which results in memory problems. The study demonstrates that BACE1 and PSEN1 methylation decrease with age and APOE status, which leads to Aβ accumulation. Hippocampal regions show decreased histone acetylation, which blocks vital gene expression required for learning, and tau accumulation results from methylation changes that damage cellular cleaning systems. These findings reveal the significant role of epigenetic processes in AD. A deeper understanding of these mechanisms not only sheds light on disease progression but also opens new pathways for treatment. This review highlights promising epigenetic targets and current challenges, encouraging the continued development of epigenetics-based therapies for AD and related neurodegenerative conditions.
References
[1] Dementia. Retrieved August 17, 2025, from https://www. who.int/news-room/fact-sheets/detail/dementia
[2] National Institute on Aging. Alzheimer’s disease fact sheet. 2023, April 5. https://www.nia.nih.gov/health/alzheimers-anddementia/alzheimers-disease-fact-sheet
[3] Knopman David S., Amieva Helene, Petersen Ronald C., Chételat Gael, Holtzman David M., Hyman Bradley T., Nixon Roger A., Jones David T. Alzheimer disease. Nature Reviews Disease Primers, 2021, 7(1), 33. https://doi.org/10.1038/s41572- 021-00269-y
[4] Scheltens Philip, De Strooper Bart, Kivipelto Miia, Holstege Harry, Chételat Gael, Teunissen Charlotte E., Cummings Jeffrey, van der Flier W. M. Alzheimer’s disease. Lancet, 2021, 397(10284), 1577–1590. https://doi.org/10.1016/S0140- 6736(20)32205-4
[5] Mary Alice, Mancuso Raffaele, Heneka Michael T. Immune Activation in Alzheimer Disease. Annual Review of Immunology, 2024, 42(1), 585–613. https://doi.org/10.1146/ annurev-immunol-101921-035222
[6] Mattson Mark P., Arumugam Thiruma V. Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. Cell Metabolism, 2018, 27(6), 1176–1199. https://doi. org/10.1016/j.cmet.2018.05.011
[7] De Plano Lucia M., Saitta Angela, Oddo Salvatore, Caccamo Angelo. Epigenetic Changes in Alzheimer’s Disease: DNA Methylation and Histone Modification. Cells, 2024, 13(8), 719. https://doi.org/10.3390/cells13080719
[8] Janczura K. J., Volmar C.-H., Sartor G. C., Rao S. J., Ricciardi N. R., Lambert G., Brothers S. P., Wahlestedt C. RETRACTED: Inhibition of HDAC3 reverses Alzheimer’s Dean&Francis Yuhe Ping disease-related pathologies in vitro and in the 3xTg-AD mouse model. Proceedings of the National Academy of Sciences, 2018, 115(47). https://doi.org/10.1073/pnas.1805436115
[9] Lyko Friedrich. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nature Reviews Genetics, 2018, 19(2), 81–92. https://doi.org/10.1038/ nrg.2017.80
[10] Gujar Hemant, Weisenberger Daniel J., Liang Gang. The Roles of Human DNA Methyltransferases and Their Isoforms in Shaping the Epigenome. Genes, 2019, 10(2), 172. https://doi. org/10.3390/genes10020172
[11] Martínez-Iglesias Oscar, Carrera Irene, Carril Juan C., Fernández-Novoa Lidia, Cacabelos Nicolau, Cacabelos Ramón. DNA Methylation in Neurodegenerative and Cerebrovascular Disorders. International Journal of Molecular Sciences, 2020, 21(6), 2220. https://doi.org/10.3390/ijms21062220
[12] Zhang Hao, Zhang Xiaoxing, Clark E., Mulcahey M., Huang S., Shi Y. G. TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Research, 2010, 20(12), 1390–1393. https://doi.org/10.1038/cr.2010.156
[13] Cochran Jason N., Geier Emily G., Bonham Laura W., Newberry James S., Amaral Michael D., Thompson Michelle L., Lasseigne Brandon N., Karydas Aristeidis M., Roberson Erik D., Cooper Grant M., Rabinovici Gil D., Miller Bruce L., Myers Richard M., Yokoyama J. S., Alzheimer’s Disease Neuroimaging Initiative. Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases. American Journal of Human Genetics, 2020, 106(5), 632–645. https://doi.org/10.1016/j.ajhg.2020.03.010
[14] Jucker Mathias, Walker Lawrence C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature, 2013, 501(7465), 45–51. https://doi.org/10.1038/ nature12481
[15] West Robert L., Lee John M., Maroun L. E. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer’s disease patient. Journal of Molecular Neuroscience, 1995, 6(2), 141–146. https://doi.org/10.1007/ BF02736773
[16] Hou Yafei, Chen Hong, He Qiang, Jiang Wei, Luo Tao, Duan Jin, Mu Nian, He Yi, Wang Hong. Changes in methylation patterns of multiple genes from peripheral blood leucocytes of Alzheimer’s disease patients. Acta Neuropsychiatrica, 2013, 25(2), 66–76. https://doi.org/10.1111/j.1601-5215.2012.00662.x
[17] Barrachina Maria, Ferrer Isidre. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. Journal of Neuropathology and Experimental Neurology, 2009, 68(8), 880–891. https://doi.org/10.1097/ NEN.0b013e3181af2e46
[18] Rogaev Eugene I., Lukiw Walter J., Lavrushina Olga, Rogaeva Ekaterina A., St George-Hyslop Peter H. The upstream promoter of the beta-amyloid precursor protein gene (APP) shows differential patterns of methylation in human brain. Genomics, 1994, 22(2), 340–347. https://doi.org/10.1006/ geno.1994.1393
[19] Li Qian, Hermanson Patrick J., Springer Nathan M. Detection of DNA Methylation by Whole-Genome Bisulfite Sequencing. Methods in Molecular Biology, 2018, 1676, 185– 196. https://doi.org/10.1007/978-1-4939-7315-6_11
[20] Jarmasz Jason S., Stirton H., Davie J. R., Del Bigio M. R. DNA methylation and histone post-translational modification stability in post-mortem brain tissue. Clinical Epigenetics, 2019, 11(1), 5. https://doi.org/10.1186/s13148-018-0596-7
[21] Hampel Henrik, Vassar Robert, De Strooper Bart, Hardy John, Willem Marc, Singh Neeraj, Zhou Jin, Yan Rong, Vanmechelen Eric, De Vos An, Nisticò Rita, Corbo Michele, Imbimbo Biagio P., Streffer Jens, Voytyuk I., Timmers Maartje, Tahami Monfared A. A., Irizarry Manuel, Albala B., Koyama A., … Vergallo Alessandro. The β-Secretase BACE1 in Alzheimer’s Disease. Biological Psychiatry, 2021, 89(8), 745–756. https:// doi.org/10.1016/j.biopsych.2020.02.001
[22] Su Yan, Wang Qi, Gao Feng, Xu Jian, Fu Jie, Ying Yu, Xia Yan, Wang Xi, Dong Qun, Shen Yi, Cheng Xia. Increased Plasma β-Secretase 1 Activity Correlates With Neurodegeneration in Cerebral Small Vessel Disease. Journal of the American Heart Association, 2024, 13(24), e036204. https://doi.org/10.1161/ JAHA.124.036204
[23] Fuso Alessio, Cavallaro Rosa A., Nicolia Valentina, Scarpa Salvatore. PSEN1 promoter demethylation in hyperhomocysteinemic TgCRND8 mice is the culprit, not the consequence. Current Alzheimer Research, 2012, 9(5), 527–535. https://doi.org/10.2174/156720512800618053
[24] Bakulski Kelly M., Dolinoy Dana C., Sartor Mary A., Paulson H. L., Konen J. R., Lieberman A. P., Albin R. L., Hu H., Rozek L. S. Genome-wide DNA methylation differences between late-onset Alzheimer’s disease and cognitively normal controls in human frontal cortex. Journal of Alzheimer’s Disease, 2012, 29(3), 571–588. https://doi.org/10.3233/JAD-2012-111223
[25] Monti Nicola, Cavallaro Rosa A., Stoccoro Anna, Nicolia Valentina, Scarpa Salvatore, Kovacs Gabor G., Fiorenza Maria T., Lucarelli Marco, Aronica Eleonora, Ferrer Isidre, Coppedè Fabio, Troen Arlin M., Fuso Alessio. CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain. Epigenetics, 2020, 15(8), 781–799. https://doi.org/10.1080/15592294.2020.1722917
[26] Sims Rebecca, Hill Michael, Williams Joanne. The multiplex model of the genetics of Alzheimer’s disease. Nature Neuroscience, 2020, 23(3), 311–322. https://doi.org/10.1038/ s41593-020-0599-5 Dean&Francis ISSN 2959-409X
[27] Yu Chia-Wei E., Cudaback E., Foraker J., Thomson Z., Leong L., Lutz F., Gill J. A., Saxton A., Kraemer B., Navas P., Keene C. D., Montine T., Bekris L. M. Epigenetic signature and enhancer activity of the human APOE gene. Human Molecular Genetics, 2013, 22(24), 5036–5047. https://doi.org/10.1093/ hmg/ddt354
[28] Tulloch J., Leong L., Thomson Z., Chen S., Lee E. G., Keene C. D., Millard S. P., Yu C. E. Glia-specific APOE epigenetic changes in the Alzheimer’s disease brain. Brain Research, 2018, 1698, 179–186. https://doi.org/10.1016/ j.brainres.2018.08.006
[29] Ma Yan, Smith C. E., Lai Chao-Qiang, Irvin M. R., Parnell L. D., Lee Y. C., Pham L., Aslibekyan S., Claas S. A., Tsai M. Y., Borecki I. B., Kabagambe E. K., Berciano S., Ordovás J. M., Absher D. M., Arnett D. K. Genetic variants modify the effect of age on APOE methylation in the Genetics of Lipid Lowering Drugs and Diet Network study. Aging Cell, 2015, 14(1), 49–59. https://doi.org/10.1111/acel.12293
[30] Lee E. G., Tulloch J., Chen S., Leong L., Saxton A. D., Kraemer B., Darvas M., Keene C. D., Shutes-David A., Todd K., Millard S., Yu C. E. Redefining transcriptional regulation of the APOE gene and its association with Alzheimer’s disease. PLoS One, 2020, 15(1), e0227667. https://doi.org/10.1371/journal. pone.0227667
[31] Xiao Xiaojing, Liu Xiang, Jiao Baohong. Epigenetics: Recent Advances and Its Role in the Treatment of Alzheimer’s Disease. Frontiers in Neurology, 2020, 11, 538301. https://doi. org/10.3389/fneur.2020.538301
[32] Anderson K. W., Turko I. V. Histone post-translational modifications in frontal cortex from human donors with Alzheimer’s disease. Clinical Proteomics, 2015, 12, 26. https:// doi.org/10.1186/s12014-015-9098-1
[33] Guo Y., Chomiak A. A., Hong Y., Lowe C. C., Kopsidas C. A., Chan W. C., Andrade J., Pan H., Zhou X., Monuki E. S., Feng Y. Histone H2A ubiquitination resulting from Brap loss of function connects multiple aging hallmarks and accelerates neurodegeneration. iScience, 2022, 25(7), 104519. https://doi. org/10.1016/j.isci.2022.104519
[34] Myung N. H., Zhu X., Kruman I. I., Castellani R. J., Petersen R. B., Siedlak S. L., Perry G., Smith M. A., Lee H. G. Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age, 2008, 30(4), 209–215. https://doi.org/10.1007/s11357-008-9050-7
[35] Ogawa Osamu, Zhu X., Lee H. G., Raina A., Obrenovich M. E., Bowser R., Ghanbari H. A., Castellani R. J., Perry G., Smith M. A. Ectopic localization of phosphorylated histone H3 in Alzheimer’s disease: a mitotic catastrophe?. Acta Neuropathologica, 2003, 105(5), 524–528. https://doi. org/10.1007/s00401-003-0684-3
[36] Lau P. N., Cheung P. Histone code pathway involving H3 S28 phosphorylation and K27 acetylation activates transcription and antagonizes polycomb silencing. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(7), 2801–2806. https://doi.org/10.1073/pnas.1012798108
[37] Chaput D., Kirouac L., Stevens S. M., Jr, Padmanabhan J. Potential role of PCTAIRE-2, PCTAIRE-3 and P-Histone H4 in amyloid precursor protein-dependent Alzheimer pathology. Oncotarget, 2016, 7(8), 8481–8497. https://doi.org/10.18632/ oncotarget.7380
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
